0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIGIT

TIGIT

Here comes a serial of ready-to-use universal ELISA kits to simplify your drug R&D. Request for free sample.

TIGIT Molecule Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:V-Set And Immunoglobulin Domain Containing 9,Washington University Cell Adhesion Molecule,V-Set And Transmembrane Domain Containing 3,WUCAM,DKFZp667A205,FLJ39873,V-set and immunoglobulin domain-containing protein 9,TIGIT,VSIG9,T Cell Immunoreceptor With I
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 3 Clinical

TIGIT Protein Product ListCompare or Buy

TIGIT Part of Bioactivity data

TIT-H5253-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

TIT-H82F1-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).

TIT-H52H3-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human TIGIT MAb (Mouse IgG1) captured on CM5 chip via Anti-Mouse antibodies surface, can bind Human TIGIT, His Tag (Cat. No. TIT-H52H3) with an affinity constant of 3.93 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

TIT-C52H7-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD155, Fc Tag (Cat. No. CD5-H5251) on Protein A Biosensor, can bind Canine TIGIT, His Tag (Cat. No. TIT-C52H7) with an affinity constant of 5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TIGIT Customer Reviews

TIGIT Molecule Synonym Name

TIGIT,VSIG9,VSTM3

TIGIT Molecule Background

TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.

TIGIT References

TIGIT Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EOS-448 EOS-448 Phase 2 Clinical Iteos Hematologic Neoplasms; Neoplasms Details
BMS-986207 BMS-986207 Phase 2 Clinical Bristol-Myers Squibb Company Ovarian Neoplasms; Neoplasms; Endometrial Neoplasms Details
IBI-939 IBI-939 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Lung Neoplasms Details
COM-902 COM-902 Phase 1 Clinical Compugen Ovarian Neoplasms; Colonic Neoplasms; Neoplasms, Plasma Cell; Breast Neoplasms; Lung Neoplasms Details
JS-006 JS-006 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours Details
AB-308 AB-308 Phase 1 Clinical Arcus Biosciences Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma Details
Vibostolimab MK-7684; MK-7684A Phase 3 Clinical Merck Sharp & Dohme Corp Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Tiragolumab RG-6058; MTIG-7192A; RO-7092284 Phase 3 Clinical F. Hoffmann-La Roche Ltd Liver Neoplasms; Lymphoma, B-Cell; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
Domvanalimab AB-154 Phase 3 Clinical Arcus Biosciences Solid tumours; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ociperlimab BGB-A1217 Phase 3 Clinical Beigene Ltd Solid tumours; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details

This web search service is supported by Google Inc.

totop